Retrospective Analysis Produced by Monarch Medical Technologies Explores the Effect of Blood Glucose Goal Range and Two-Hour Blood Glucose Checks on Hypoglycemia Incidence

    0
    231
    Reading Time: 2 minutes

    Two Posters Presented at AACE 2019 Review the Safety and Efficacy of
    Blood Glucose Goal Range and Two-Hour Blood Glucose Checks for
    Intravenous Insulin Dosing

    CHARLOTTE, N.C.–(BUSINESS WIRE)–Monarch
    Medical Technologies
    , the leader in precision insulin dosing
    technology for optimized glycemic management, presented two posters at
    the American Association of Clinical Endocrinologists (AACE) Annual
    Meeting. The two retrospective studies analyze a database of nearly one
    million blood glucose readings from approximately 45,000 patients who
    were prescribed intravenous (IV) insulin dose recommendations using the EndoTool®
    Glucose Management System
    .

    The first poster, “Measure
    of Safety for Q2Hour vs. Q1Hour Glucose Checks for Intravenous Insulin
    Dosing
    ,” aimed to determine the safety and efficacy of two-hour
    blood glucose checks when using the electronic glucose management system
    (eGMS), EndoTool.

    Many paper protocols and eGMS dosing algorithms for IV insulin make
    recommendations to change from hourly (q1hour) blood glucose checks to
    every two-hour (q2hour) checks based on various measures of the
    subject’s blood glucose stability. However, it is suggested that the
    algorithms should be evaluated based on the incidence of hypoglycemia
    and variability. This analysis found that measures of hypoglycemia and
    control were superior for q2hour checks compared to q1hour checks,
    confirming that the EndoTool algorithm for recommendation of q2hour
    checks is appropriate.

    “The ability to move to q2hour blood glucose checks benefits the patient
    and significantly improves nursing workflow and the cost of care,” said
    Laurel Fuqua, Executive VP & Chief Clinical Officer of Monarch Medical
    Technologies. “However, this transition must be made at the appropriate
    time to ensure patient safety. This study confirms that the EndoTool
    algorithm is appropriate and safe in its recommendation.”

    The second poster, “Goal
    Range Effect on Hypoglycemia Incidence for Intravenous Insulin Dosing

    examined the effect of goal range on the incidence of hypoglycemia in
    patients receiving intravenous insulin therapy.

    Most eGMS and paper protocols require users to set an upper goal and
    lower goal, referred to as the goal range. Target blood glucose values
    for the glucose range vary, and limited research exists to study the
    effect of goal range on hypoglycemia. This retrospective analysis
    stratified two goal ranges, 100 to 140 mg/dL and 160 to 200 mg/dL, and
    analyzed the incidence of hypoglycemia in sub-ranges of 10 mg/dL. The
    analysis concluded that as the upper goal is lowered, reducing the
    spread of the goal range has the potential to reduce hypoglycemia.

    “While the EndoTool algorithm has statistically eliminated hypoglycemia,
    we continue to look for enhancements to completely eliminate the risk of
    hypoglycemia,” said W. Patrick Burgess, Founder & Inventor of EndoTool.
    “Further research is required; however, our analysis supported the
    hypothesis that reducing the goal range spread as the upper goal is
    lowered could make a significant difference in reducing hypoglycemia.”

    To download the two posters and learn more about Monarch Medical
    Technologies, please visit monarchmedtech.com.

    About Monarch Medical Technologies

    Monarch Medical Technologies is the leading provider of electronic
    systems for inpatient glycemic management. Monarch’s EndoTool® Glucose
    Management System offers personalized dosing recommendations for
    intravenous and subcutaneous insulin therapy. As a Class II FDA-cleared,
    patented software suite, EndoTool has been chosen by more than 300
    hospitals to provide unsurpassed patient-specific glycemic control
    across a broad population of patients, and ultimately deliver better,
    safer care. For more information, please visit monarchmedtech.com.

    Contacts

    Flannery Nangle
    Monarch Medical Technologies
    315-406-5495
    [email protected]